Merck (NYSE:MRK) has taken a significant equity stake in Eikon Therapeutics, expanding its presence in oncology-focused ...

This genomics stock appears to be at an inflection point.

​Guardant Health, Inc. (NASDAQ:GH) is one of the Best Russell 2000 Stocks to Buy Right Now. Wall Street has a positive opinion on Guardant Health, Inc. (NASDAQ:GH). Recently, on January 19, Guardant ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it entered into privately negotiated exchange ...

Shield’s FDA-approved blood test drives cancer screening growth, pricing power, and cash-flow upside. Click for this GH ...

New Guardant Reveal offering provides oncologists with tissue-free solution to monitor treatment response and detect early disease progression with unprecedented speed and sensitivity Reveal is ...

Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of its upsized offering of $350.0 million aggregate principal amount of 0% ...

New Guardant Hereditary Cancer test offers germline testing to identify guideline-recommended genetic variants associated with cancer risk across 12+ tumor types Results help guide treatment decisions ...

Guardant’s test analyzes circulating tumor DNA that is then used to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with the Braftovi combo therapy ...

Partnership will Make Guardant Health Cancer Tests Available to Over 250 Million Patients with a Record in Epic Integration Will Simplify the Process for Clinicians to Order Tests and Access Results ...